Quick Take: Several factors explain the top reasons to get bullish on biotech, including a potential multi-year growth cycle driven by medical approvals and increased Big Pharma M&A activity. Key areas to watch include FDA-approved gene editing therapies from companies like CRISPR Therapeutics (CRSP), the $130 billion obesity treatment market led by Eli Lilly (LLY), and precision oncology treatments such as antibody-drug conjugates (ADCs).
Why the Biotech Sector Is Poised for Massive Growth
Biotech stocks offer some of the most explosive opportunities.
That is, if you spot the right ones.
For example, some of the hottest ideas can be found in weight loss drugs, cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing.
3 High-Growth Breakthrough Innovations in Biotech
1. Gene-Editing Therapies: CRISPR Therapeutics (NASDAQ: CRSP)
Look at CRISPR Therapeutics (SYM: CRSP), for example. Not long ago, it received US FDA approval for its gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.
With that news, we watched CRISPR jump from about $40 to $70.
2. Weight Loss & Obesity Megatrend: Eli Lilly & Co. (NYSE: LLY)
Or, look at Eli Lilly (SYM: LLY). Thanks to strong demand for obesity medication, the stock exploded. Novo Nordisk, Viking Therapeutics, and Structure Therapeutics also pushed higher. Even better, all could push even higher on growing demand for obesity medications. Helping, Goldman Sachs just said the obesity treatment market could be a $130 billion opportunity.
Pharmaceutical leaders with proprietary patent portfolios possess strong economic moat stocks characteristics, enabling long-term pricing power.
3. Next-Gen Oncology: Antibody-Drug Conjugates (ADCs)
Investors balancing high-growth biotech stocks with income-generating assets can use Portfolio Payouts to track recurring cash flow.
Accelerating M&A Activity: Big Pharma’s Shopping Spree
What makes biotech even hotter is that major drug companies are on a shopping spree.
Over the next few years, drug giants could lose billions to patent expirations. According to EY analysts, the top 20 giants could lose about $180 billion in sales by the end of the decade. To stop some of the potential bloodshed, companies are building up their pipelines, bringing in fresh new drugs with multi-billion-dollar potential. For example, most recently, Johnson & Johnson said it would acquire Ambrx Biopharma for $2 billion. Pfizer acquired Seagen for $43 billion.
Of course, there are many more reasons to get bullish. But you get the point.
Frequently Asked Questions About Biotech Stock Investing
Q1: Why are gene-editing companies like CRISPR Therapeutics significant?
A: CRISPR Therapeutics (CRSP) achieved landmark FDA approval for its CRISPR-based therapy (Casgevy) for sickle cell disease and beta-thalassemia, proving that commercial gene editing is viable and opening up multi-billion dollar curative treatment markets.
Q2: How big is the projected obesity drug market for biotech companies?
A: Major financial institutions like Goldman Sachs project that the global obesity treatment market could reach $130 billion by 2030, benefiting market leaders like Eli Lilly (LLY) and Novo Nordisk.
Q3: Why is Big Pharma buying smaller biotech companies?
A: Large pharmaceutical companies face upcoming patent cliffs on older drugs. To replenish their revenue pipelines, they acquire innovative clinical-stage biotech companies specializing in ADCs, rare disease gene therapies, and metabolic health.
Found this helpful? Share it with others.
Written by Ian Cooper